Vaxil Bio Ltd. VXLLF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 89.51% | 62.91% | 345.07% | -28.17% | -13.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.51% | 54.07% | 345.07% | -28.17% | -13.03% |
| Operating Income | -89.51% | -54.07% | -345.07% | 28.17% | 13.03% |
| Income Before Tax | -277.69% | -59.84% | -- | 45.08% | 184.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -277.69% | -59.84% | -- | 45.08% | 184.69% |
| Earnings from Discontinued Operations | -- | -- | 114.01% | -- | 184.31% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.97% | -59.84% | 2,704.46% | 59.61% | 184.92% |
| EBIT | -89.51% | -54.07% | -345.07% | 28.17% | 13.03% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -204.50% | -10.11% | 2,398.25% | 59.54% | 184.73% |
| Normalized Basic EPS | -223.73% | -9.91% | -- | 45.00% | 184.29% |
| EPS Diluted | -204.50% | -10.11% | 2,398.25% | 59.54% | 184.73% |
| Normalized Diluted EPS | -223.73% | -9.91% | -- | 45.00% | 184.29% |
| Average Basic Shares Outstanding | 45.42% | 45.42% | 13.94% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 45.42% | 45.42% | 13.94% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |